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ABSTRACT
Changes in legislation have affected supply routes of new psychoactive substances such as
synthetic cannabinoids with evidence of supply over the darknet. We identified darknet drug
markets using an index database and Tor Browser to access markets. We identified SC in prod-
uct listings using a custom-programmed script. We collected data at bimonthly intervals (August
2016–April 2017). Eleven darknet markets listed SC for sale, the largest number from China, UK,
US, Netherlands, and Germany. Formulations available were high purity powder/crystal, smoking
preparations and vape preparations. The top five listed compounds from China across the time
points were FUB-AMB, ABD-FUBINACA, 5F-NPB-22, MAB-CHMINACA, and NM-2201. 5F-CUMYL-
4CN-PINACA was unavailable at early time points but emerged during the study. Cost of high
purity formulations from China ranged from 1.3 to 3.1 Euro per gram for quantities 1000 g.
Europe and North America accounted for 99% smoking preparations predominantly in small
packages (<50g). SC are widely available on the darknet with availability changing over time.
High purity formulations are predominantly available from China in quantities up to kilograms
with price per gram reducing with increased quantity. Small packages of ready-made smoking
mixtures are available from Europe and North America.
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Darknet; dark web;
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Background
With expansion of the World Wide Web in the late
1990s, internet-based forums relating to drug use and
internet sites specifically marketing drugs began to
proliferate [1]. In the 2000s, there was an increasing
market for the online sale of prescription-only medi-
cine and new psychoactive substances (NPS) over the
internet opening the drugs market to a wider audi-
ence. However, it was relatively easy for law enforce-
ment to track transactions for illicit drugs between
sellers (or vendors) and buyers on the open (surface)
web. It was only with improved email encryption, and
later anonymity networks combined with electronic
cryptocurrencies, such as bitcoin, that anonymous on-
line transactions became possible. As a result, in early
2010 hidden darknet or cryptomarkets began to
emerge. Initially, these cryptomarkets were used for
sale of traditional recreational drugs such as cannabis,
opioids, cocaine, and synthetic stimulants such as 3,4
methylene dioxymethamphetamine (MDMA) [2],
whilst prescription-only and NPS remained available
on open web [3–6]. Classification of NPS in many
countries and the introduction of the UK
Psychoactive Substance Act in 2016 and similar legis-
lation in other countries has impacted upon supply
routes, potentially increasing sale through darknet
markets [7].
Cryptomarkets function in a similar way to online
trading websites such as eBayTM or AmazonVR , but to
avoid detection use anonymity networks such as Tor
(The Onion Router) that allow for hidden services.
Tor is free software that enables online anonymity
using a process known as onion routing to encrypt
and transmit data through a series of network nodes
to hide the user’s location. When a buyer and seller
agree upon a transaction, the buyer transfers crypto-
currency to an escrow in the darknet marketplace.
The seller receives the funds after the buyer confirms
receipt of product. As with all online marketplaces,
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ratings play a key role in identifying trustworthy
buyers and vendors but the key difference with
darknet markets is the anonymity—buyers and sellers
only know one another only by their online pseudo-
nyms. Some darknet markets only admit new users
with referral from existing users offering a further
layer of protection.
Cryptomarkets are part of a dynamic process; as
old markets close, new ones emerge. After law
enforcement activity forced the closure of one of the
most well-known darknet market—the Silk Road—in
2013, other cryptomarkets rapidly emerged. Closures
of darknet markets are commonly due to raids from
law enforcement, exit scams (where money held in
escrow is removed by site administrators prior to
order completion), hacking of marketplaces, or volun-
tary closure. A review of 103 darknet markets showed
most remained active for just over 8months [2]. The
sale of drugs on the darknet is a global phenomenon,
from 2011 to 2015 sales from EU, Norway, and
Turkey accounting for 46% of global sales value,
amounting to 79 million Euro compared to 93 million
Euro for the rest of the world [8]. Within Europe, the
majority of the drug trade on the darknet occurs in
United Kingdom, Netherlands, and Germany [2].
Over the past 10 years, there has been a rapid
increase in the availability of synthetic cannabinoids
(SC) for recreational purposes as NPS. Between 2009
and 2016, there were 739 NPS reported to the United
Nations Office on Drugs and Crime (UNODC) from
106 countries or territories. Of these NPS, SC make
up the largest category, accounting for 32% [9]. They
are also the largest group of substances monitored by
the EU Early Warning System, with a total of 169 SC
having been notified to the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) by
the end of 2016 [10]. SC are most commonly smoked
after being dissolved in solvent and sprayed onto
plant material but can also be vaped, used in topical
oil or ingested. They are potent drugs that are rela-
tively cheap to purchase and difficult to detect on
standard occupational and other drug screening pro-
grammes, which has resulted in high levels of use in
certain groups including the homeless, military, and
prisoners [11–13]. There are many different street
names for SC but spice is the most commonly used
generic term. SC demonstrate high affinity binding to
cannabinoid receptors and produce a variety of effects
from euphoria and relaxation to agitation and para-
noia [14]. Their use has also been associated with
seizures, acute kidney injury [15], and arrhythmias
[16]; with numerous fatalities associated with their
use reported from around the world, for example 29
deaths were associated with MDMB-CHMICA in
Europe between 2014 and 2015 [17]. In the US, there
have been reports of mass intoxication or “Zombie”
outbreaks caused from use of SC [18]. There has been
anecdotal evidence of increasing supply of NPS
on the darknet therefore we aimed to determine the
profile of synthetic cannabinoid availability on the
darknet between August 2016 and April 2017.
Methods
We performed a study of publicly available darknet
drug markets that were hosted on Tor hidden
services, i.e. the darknet. The darknet drug markets
were discovered through an Internet-facing index
(deepdotweb.com) that is a frequently updated data-
base of accessible darknet cryptomarkets with lists of
currently available sites (and those which have been
taken down, or might be scams, or have disappeared
for other reasons). An exhaustive list of addresses and
(where appropriate) referrals were taken from
DeepDotWeb for drug-selling cryptomarkets from
this site to establish accounts at each market where
needed—some were open to browsing without
accounts. No search terms were needed to identify
which cryptomarkets sold drugs—there was a simple
list that was maintained frequently by the administra-
tors of the site, based on community input and new
drug markets submitting their details to the site. The
list that we curated over the span of the data collec-
tion activities kept the addresses of all markets origin-
ally indexed on DeepDotWeb, and those that were
removed from the DeepDotWeb index in later data
collection activities were verified to have disappeared.
Sometimes there were explanations for the disappear-
ances given on the DeepDotWeb site, such as FBI
takedowns, but not always. Given the nature of the
darknet, however, verifying the exhaustiveness of this
list was impossible. Thus, although we made every
effort to be exhaustive in our data collection, we can
still only describe our study as descriptive. The Tor
Browser (tor.com) was used to access the drug
markets via their .onion addresses.
As darknet drug markets are highly volatile, we
established a list at the beginning of the project with
each of the markets tested and the list added to as
new markets emerged. We excluded markets or sellers
unlikely to traffic in SCRAs (e.g. markets dedicated to
lysergic acid diethylamide (LSD)) and markets requir-
ing authentication beyond usernames, passwords,
and PGP keys (Pretty Good Privacy: a widely-used
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encryption program for encrypting and decrypting
data communications) were not included in the sam-
ple. Tor-enabled discussion boards where sales were
made rather than traditional eBay-style markets were
also not included. After logging into each drug mar-
ket site, listings of SC were identified by navigating to
the cannabis/synthetics pages (this was the usual cat-
egorisation for SCRAs across markets). Each listing
was saved manually using the Tor browser’s “Save
As…” functionality. This is significantly different
from approaches using web spiders [19–21], as cur-
rent darknet drug markets are concerned about
Distributed Denial of Service (DDOS) attacks and
shut out automated scraping tools that request pages
too frequently. Manual handling of data was under-
taken to filter out listings that were obviously not SC
(e.g. miscategorised or spam listings). The collection
of listings was verified by comparing the number of
records saved against those reported by the market
(each market reported a total number of listings in
each category). One site, AlphaBay, had erroneous
listing numbers, greatly inflated the numbers of list-
ings that it advertised. These listing numbers were
checked manually by counting the number of pages
of listings, with 25 listings per page. The HTML data
for each listing page was saved and catalogued in a
directory structure identifying the date and market it
was taken from. Each site had a custom program
written for it in Python, an open source scripting lan-
guage, to extract data (e.g. price, location, shipping
information, descriptions) from each listing’s HTML
page using the lxml parsing library. The script
extracted data into a comma-separated value (CSV)
file for analysis. All data was saved to a secure drive
and shared using a secure data share facility within
De Montfort University and the University of Sydney.
Snapshot data was collected at a single time point,
at two-monthly intervals from August 2016 to April
2017. After collection, data was transferred to
Microsoft Excel and analysed. Cost calculations were
converted from product listing in bitcoin to Euro
using the exchange rate at each time point using the
currency conversion website www.XE.com. Chemical
compounds or brands, formulation of synthetic can-
nabinoid preparation, weight, and cost were obtained
from title of listing or from the product description.
Location of vendors was recorded, where this was
unclear from product listing these were categorised
“unknown.” The study was granted ethical approval
from De Montfort University Ethics Committee,
Leicester (Reference 1516/352).
Results
Across the five study time points, 31 darknet drug
markets were screened, 11 were identified listing syn-
thetic cannabinoid products for sale. The three largest
darknet markets selling SC were AlphaBay (mean 171
SC listed for sale per study time point), Dream
Market (mean 163), and Valhalla (mean 86). At each
study time point, there were approximately 500
synthetic cannabinoid items listed for sale on the
darknet (range 396–576). Table 1 shows darknet
markets with SC available and the combined cost
of listings.
We identified 38 individual or combination syn-
thetic cannabinoid compounds and 24 branded SC
products, these are shown in Table 2. Vendors from
12 countries listed SC for sale. China had the largest
number of synthetic cannabinoid items listed at each
study time point (ranging from 188 [February 2017]
to 245 [October 2016]). There was variability in the
number of SC in other countries, the remainder of
the top five selling countries varied between the US,
UK, Germany, and the Netherlands (Table 3).
During the study, there were a total of 2314 dar-
knet listings for SC, the most common descriptors
were high purity (>98% pure in product description)
powder/crystal (1206 (52%) listings) and ready-made
smoking preparations (1075, 46%); vape preparations
were less common (32, 1%) and a single listed item
for blotters. High purity powder or crystal formula-
tions were predominantly available from vendors in
China (87%, 1048/1206), followed by Unknown (6%,
68/1206), Poland (2.7%, 33/1206), Spain (2.1%, 25/
1206), Finland (1%, 11/1206), US (1%, 11/1206), and
UK (0.7%, 9/1206). In contrast, listings for smoking
mixtures were almost exclusively available from
Europe (78%, 838/1075) and the US (20.6%, 221/
1075) with a small amount from Australia (0.5%,
5/1,075) and Unknown 1% (11/1075). All Chinese SC
listings were for high purity powder or crystal, prices
for these ranged from 2.4 to 25.5 Euro per gram for
quantities less than 100 g decreasing to 1.3 to 3.1 Euro
per gram for 1000 g. The top five listed compounds
from China across the time points were FUB-AMB,
ABD-FUBINACA, 5F-NPB-22, MAB-CHMINACA,
and NM-2201. With all compounds the price per
gram was greater for smaller purchase amounts and
cost reduced with increased quantities; the top five
listed compounds by Chinese vendors and price per
gram in Euro are shown in Table 4. Darknet listings
for SC from Chinese vendors contained detailed
scientific information in approximately half of listings
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as shown in the following examples (cost in Euros
added for comparison):
ADB-FUBINACA 1kg, 4.27 BTC (2,731.22 Euro).
Formula Name: N-(1-Amino-3,3-dimethyl-1-oxobutan-
2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
CAS: 1445583-51-6 Formula: C21H23FN4O2 Exact
Mass: 382.4 Molecular weight:382.43 g/mol.
Compound purity:>99%
NM-2201 1kg, 4.33 BTC (2,233.07 Euro). NM2201 is
an analog of AM2201, the potent synthetic
cannabinoid (CB) with Ki values of 1.0 and 2.6 nM
for the central cannabinoid (CB1) and peripheral
cannabinoid (CB2) receptors. The physiological
actions of NM2201 have not been characterized. This
product is intended for forensic and research
applications.
When specific SC compounds were unavailable,
Chinese darknet vendors often suggested alternatives;
MMB-Chminaca/MMBC powder, it is the best
replacement of AB-Chminaca powder. White powder,
the purity is at least 99.0%.
1000g NM-2201 powder, the best replacement of
JWH-018, 100% Shipping Warranty, No
signature required.
ADB-FUBINACA was the most commonly listed
synthetic cannabinoid from Chinese vendors but
availability declined over the study from 43 (August
2016) to 23 (April 2017). 5F-CUMYL-4CN-PINACA
was unavailable at early time points but emerged in
December 2016 with 21 items. SC from Chinese ven-
dors and the numbers listed for the study are shown
in Figure 1.
Interestingly, all 33 listings for SC products from
Poland were for high purity powder of MMB-
CHMINACA or 5F-MDMB-2201. Price per gram of
SC was more costly than Chinese vendors markets
with equivalent price of 5.6–12.3 Euro per gram for
smaller quantities 25 g and 2.8 to 3.3 Euro per gram
or quantities 500 g or more. However, Finnish
vendors listing powdered SC were by far the most
expensive selling very low quantities (1 g or less) at
equivalent price of mean 160 Euro per gram (range
105–283, n¼ 11 listings).
Vendors from within the European Union (EU)
promoted greater chance of successful delivery as seen
in this listing from Poland;
20 grams of 5F-MDMB-2201 methyl-2-(1-(5-
fluoropentyl)-1H-indole-3-ylcarbonylamino)-3,3-dime
thylbutanoate a very potent CB1/CB2 receptor
agonist, structurally related to MMB-2201. This
product is intended for research and forensic
applications. Products are sent from EU (Poland) soTa
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your package will be not suspicious because they are
send from EU not from China. How we all know
that most of parcels from China are captured by
customs offices. You can also order a sample to
check our competence and quality of product. All my
products are laboratory tested.
A Spanish vendor offered instructions on how to
make “spice”;
You make order-get powder from me. Then Finalize
order. After you get Full instruction How to make
Spyce blends. All ingriedients [sic] cost about
35euros. You made about 2-2,6 KG Spyce herbal
Across all study time points, there were 1075
ready-made smoking mixtures listed. Many of these
were small packages 5 g or less (357, 33.2%) with the
majority being 50 g or less (812, 75.5%). Price per
gram of ready-made smoking preparations also
reduced with increasing quantity purchased and
varied with country of sale. For smaller volumes (5 g
or less) France was cheapest, mean 3.33 Euro per
gram followed by Portugal 4.38, Netherlands 9.95, UK
11.57, US 11.95, Germany 12.50, Austria 15.57, and
Spain 16.48.
A Spanish vendor directly referred to the UK psy-
choactive substance act to market their product again
highlighting delivery from within EU;
UK residents here is an opportunity to make some
low risk money, since the psychoactive ban come
into effect there is many addicts not knowing where
to get it from at any price, I ended up with a ton of
it so hit me up if u wanna make money! Bulk bag of
strong shit, ideal money maker! sells for up to $30
per gram, Sent from within the EU!
Others warned of the strength of their product, the
following is a listing for a smoking mix from a
UK vendor;
7g of the Synthetic Cannabanoid known as Spice. This
batch is blueberry flavoured and contains AKB-48F,
PB-22 & AB-CHMINACA. This was a legal high in
the UK untill [sic] very recently, it is extremely strong
Table 2. List of synthetic cannabinoid chemical compounds and brand names available across study (mean number of listings
per time point).
Individual or combination synthetic cannabinoid compound (mean number of listings per time point)
5F-ADB (2.8) AB-PINACA (14.4) JWH-081 (0.2)
5F-ADB-FUB (0.2) ABD-FUBINACA (1.2) JWH-122 (1.6)
5F-AKB48 (3.2) ADB-FUBINACA (39.2) JWH-210 (2.2)
5F-AKB-57 (0.4) AKB-48 (0.8) MAB-CHMINACA (22.8)
5F-CUMYL-4CN-PINACA (11.8) AKB-48 þ UR-144 (0.8) MDMB-CHMICA (10.6)
5F-MDMB-2201 (6.4) AKB-48F, PB-22 & AB-CHMINACA (16) MMB-CHMINACA (16.8)
5F-MDMB-2201 þ FUB-AMB (0.6) AM-2201 (0.2) NM-2201 (24.4)
5F-MN-22 (3.4) CUMYL-5F-PINACA (2.4) NM-2201 þ FUB-AMB (1.6)
5F-NPB-22 (12.2) EAM-2201 (1.4) SDB-005 (5.4)
5F-PB-22 (11.8) FUB-AKB (19) THJ-2201 (14.4)
5F-PB-25 (0.2) FUB-AMB (39.4) UR-144 (1.4)
AB-CHMINACA (1.0) FUBINACA (0.4) UR-144 þ JWH-122þ JWH-210 þ AKB-48 (0.6)
AB-FUBINACA (6.2) JWH-018 (0.6)
Brand of synthetic cannabinoid
AK48 Fairly Legal Kronic
Angrybirds Game Over! Kush
Axa Blends Geeked Up Liberty Liquids
Bizarro Gorilla Glue Indoor Soil Scooby Snacks
Blue Dream Green Buddah Spice diamond
Bonzai Green Giant Strong Spice
Diablo Herbal Incense Weekend Blend
Table 3. Origin of vendors selling synthetic cannabinoids (SC) on darknet markets and the number of SC listed items per
time point.
Country of vendor 23-August-16 31-October-16 21-December-16 24-February-17 21-April-17
Australia 0 1 1 1 2
Austria 5 0 0 0 0
China 198 245 218 188 199
Finland 3 2 2 2 2
France 10 11 5 5 6
Germany 6 63 7 56 52
Netherlands 29 42 41 60 61
Poland 0 1 3 16 13
Portugal 0 0 11 10 11
Spain 3 9 19 17 12
United Kingdom 34 130 66 45 46
United States 89 54 49 22 20
Unknown 19 18 18 20 36
Total 396 576 440 442 460
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Table 4. Number of synthetic cannabinoids listed and price per gram in Euro by weight of most frequent Chinese vendor
listings across darknet markets per time point.
Compound 23 August 2016 31 October 2016
21 December
2016 24 February 2017 21 April 2017
FUB-AMB 35 45 28 25 36
<100 g 16 5.21 19 9.74 10 9.85 10 10.8 16 8.28
100 g 7 3.98 8 4.32 7 4.90 6 4.71 7 4.07
200 g 2 2.57 3 2.70 2 3.11 1 3.03 3 2.59
500 g 6 2.51 9 2.32 6 2.47 6 2.35 6 2.34
1000 g 4 1.75 6 1.85 3 2.10 2 2.01 4 1.89
ADB-FUBINACA 40 43 36 25 23
<100 g 16 7.93 18 10.54 20 9.23 16 11.57 11 10.61
100 g 6 5.00 6 5.76 6 5.34 4 5.53 5 4.86
200 g 3 2.61 2 2.74 1 3.18 1 3.03 2 2.95
500 g 12 2.44 9 2.66 4 3.06 2 3.12 2 3.08
1000 g 3 2.19 8 2.02 5 2.18 2 2.60 3 1.85
5F-NPB-22 21 32 35 33 27
<100 g 8 7.32 12 7.28 11 7.78 12 7.70 10 7.25
100 g 2 4.65 3 4.70 3 5.04 3 4.85 3 4.80
200 g 4 4.08 6 4.08 7 4.41 6 4.15 5 4.24
500 g 5 2.17 7 2.22 9 2.38 8 2.24 6 2.27
1000 g 2 1.89 4 1.93 5 2.07 4 1.98 3 1.97
MAB-CHMINACA 25 26 23 20 17
<100 g 12 5.49 13 6.44 12 9.04 10 9.24 9 9.13
100 g 5 3.92 5 3.32 5 5.21 5 4.96 2 3.25
200 g 3 2.64 3 2.70 2 3.11 2 2.96 2 2.95
500 g 4 1.92 2 2.35 2 2.52 1 2.42 2 2.39
1000 g 1 1.96 3 2.00 2 2.14 2 2.04 1 2.04
NM-2201 21 25 13 18 19
<100 g 5 6.27 10 6.50 3 6.31 8 7.12 8 6.56
100 g 6 3.69 5 3.71 4 4.39 3 3.77 4 3.63
200 g n/a 1 1.62 n/a n/a 1 1.77
500 g 6 2.51 5 2.47 3 2.79 4 2.56 3 2.58
1000 g 4 1.61 4 1.95 3 2.21 3 2.06 3 1.85
Figure 1. Number of synthetic cannabinoids listed for sale from Chinese vendors.
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and unless you are an experienced user of this type of
product I would strongly urge you not to order this, it
will be too strong for you to enjoy and certainly not a
drug you would want to take up as a new user.
Vendors from five countries offered larger quanti-
ties (500 g) of smoking mixes accounting for 12.2%
(131/1075) of darknet listings for SC smoking prepa-
rations. For these larger volumes, Netherlands was
cheapest with mean price 1.50 Euro per gram, fol-
lowed by France 1.63, Germany 1.71, Spain 1.92, and
UK 2.87.
There were 32 listed vape products containing SC
from UK (11), Unknown (11), Germany (6), US (2),
and Netherlands (2). Twelve contained SGT-25
(known as 5F-CUMYL-PINACA), one contained
JWH-081 and 19 were branded vape products such as
K2 and Kronic. Price was more variable but still lower
for higher volumes 2.2 to 3.0 Euro per ml for
100ml and 3.56–57 Euro per ml for 1–5ml. The sin-
gle SC listed item for blotters consisted of 10 3mg
blotters of JWH-018.
Discussion
The use of the darknet for the sale of illicit drugs is a
rapidly emerging market. Data collected by the Global
Drug Survey in 2012 of 9470 respondents from pre-
dominantly male population with mean age in
20s–30s from US, Australia, and UK revealed that 65,
53, and 40%, respectively had heard of the Silk Road
[22]. MDMA, cannabis, and LSD were the most com-
monly purchased drugs. Their study found the most
common reasons for buying drugs from Silk Road
were wider range of products available, superior qual-
ity, convenience, and the use of vendor rating system.
Those who avoided the Silk Road either reported
adequate access to drugs or fear of being caught. Data
from their follow-up survey [23] revealed in UK
25.5% (n¼ 3118) reported having obtained drugs on
the darknet in the past 12months. Lower rates were
reported in the US, 13.2% of respondents (n¼ 5655),
Germany 6% (n¼ 20,298), and Netherlands 6.7%
(n¼ 1433). Finland had the highest rate of drug use
from darknet but from a smaller sample size (41.4%,
n¼ 244). According to EMCDDA, the three top
European countries in order of revenue and weight of
sales of drugs on the darknet are Germany, United
Kingdom, and Netherlands with approximately 27, 21,
and 18 million Euro, respectively [2]. Despite German
markets having the most revenue, it appears more
people in the UK access the darknet suggesting buyers
and vendors may differ in location or reflect
quantities purchased per transaction. In our study,
there were more darknet vendors selling SC in UK
than Germany (20 vs 8) and a larger number of SC
products (321 vs 184) implying countries vary in the
type of drugs they buy on the darknet. Although it
remains the largest number of synthetic cannabinoid
products available on the darknet in Europe originate
from these three countries (see Table 3).
Darknet markets are volatile—over the course of
the study several darknet markets were either tempor-
arily or permanently disabled and two markets
switched to a referral-only system, meaning new
buyers had to be referred by existing members.
During the study, two new darknet markets selling
SC emerged. At the final time point, 9 out of 11 dar-
knet markets selling SC remained open with one of
these no longer accepting new members. After the
study, two of the largest darknet markets—Hansa and
AlphaBay—were closed by law enforcement in June
and July 2017. When AlphaBay was shut down, there
were more than 350,000 listed illicit items including
drugs and chemicals (approximately 200,000), fire-
arms, and cybercrime malware with a conservative
estimation of 1 billion US dollars transacted since the
market was created in 2014 [2].
A geographical analysis of trafficking on a popular
darknet market showed Chinese vendors specialised in
selling NPS [24], and the European Drug Report also
suggests Chinese laboratories are the source of many
NPS [25]. This is consistent with our data, showing
large number of SC available from China. These high
purity SC are available in quantities up to 1 kg with
the price per gram reducing with increasing quantity
purchased. Given the large quantities available, detailed
scientific information and frequent descriptions of
laboratory tested high purity this suggests these are not
being sold to individual end-users, especially given the
typical micro- to milligram dosing for SC. It is likely
that the larger quantity amounts are being marketed
for others to be processed packaged and sold on locally
through other channels. The increased scrutiny of SC
exported from China may explain why some darknet
vendors from EU such as Poland, Spain, and UK are
exploiting less stringent shipping within the EU for
sale of high purity preparations.
Ready-made smoking mixtures (“spice”) were the
second major category of SC available on the darknet.
These are most commonly available from Europe and
North America with the majority of these offered in
small volume packages of less than 50 g, suggesting
that these are potentially being marketed more
towards end-users of the product(s).
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The main limitations of our study were darknet
listings for SC correspond only to products offered
for sale. As we did not purchase or analyse the com-
pounds listed, we were unable to confirm definitively
the SC present within the products. Given the ano-
nymity afforded by the use of cryptocurrencies, it is
difficult to determine actual sales. Some darknet sites
such as Dream Market offer vendor details on
“number of successful transactions” which can give
some idea of sales over time, although it is often
unclear the product or quantity of item sold. It is also
possible SC listed on the darknet were not identified
by our search methodology. This may have occurred
if they had been inadvertently placed in a different
drug category by the listing vendor. Finally, it is pos-
sible that some markets that existed in the time
period were not included. The darknet allows for sites
that are only accessible by those who have been given
the direct addresses by the owners, and that are not
indexed by search engines or manually curated lists.
However, if these invite-only sites are similar to the
publicly advertised invite-only sites, the invitations act
as a “VIP” status to high level sellers who also adver-
tise their wares on public markets.
Introduction of policies such as The Psychoactive
Substances Act may impact the use of the darknet
over time for NPS markets [26]. Given the rapidly
changing environment of darknet drug markets, it is
vital for policy makers to be aware of available sub-
stances as seen with the emergence of 5F-CUMYL-
4CN-PINACA during the study. It will be interesting
to see the effect of the closure of two large darknet
markets (AlphaBay and Hansa) on the availability of
SC on the darknet and whether vendors switch to
other marketplaces, develop new marketplaces or util-
ise alternative sales platforms. Data on snapshots of
the availability of NPS on the open web is routinely
included in the Risk Assessment process of NPS at
the EMCDDA. The development of methodology to
determine the availability of NPS on the dark web
will widen the scope of these assessments and ensure
that the risk assessment process is guided by informa-
tion which more accurately reflects the availability of
NPS to users. The technological capacity to monitor
drug markets needs to evolve alongside and in close,
cross-disciplinary communication with toxicological
and policy responses to this dynamic field.
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